On Thursday, Shares of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), dropped -4.37% to $56.72.
Isis Pharmaceuticals, declared it has earned a $10 million milestone payment from Biogen associated with the validation of an unrevealed target to treat a neurological disorder. This is the ninth program to advance, which comprises four drugs in development, under Isis’ and Biogen’s broad planned alliance to discover and develop novel therapies to treat neurological and neuromuscular disorders.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
Shares of VIVUS Inc. (NASDAQ:VVUS), declined -4.29% to $2.23, during its last trading session, hitting its lowest level.
VIVUS, declared that it will provide an update and report financial results for the first quarter ended March 31, 2015 after the NASDAQ Market closes on Tuesday, May 5, 2015. The company will conduct a conference call and an audio webcast at 4:30 pm EDT the same day.
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union.
At the end of Thursday’s trade, Shares of Armstrong World Industries, Inc. (NYSE:AWI), dwindled -4.23% to $54.74.
Armstrong World Industries, stated first quarter 2015 results.
Not taking into account the unfavorable impact from foreign exchange of $20 million, merged net sales reduced 3.3% contrast to the preceding year period driven by lower volumes across all businesses which more than offset the impact from favorable price and mix.
The decline in operating income and net income contrast to the preceding year period was influenced by higher non-cash U.S. Pension expense and separation costs related to the formerly declared spin-off of the Flooring business. The declines in operating income and net income were also driven by the margin impact of lower volumes, raised SG&A expense and lower earnings from WAVE, which were only partially offset by favorable price and mix. The decline in net income was also influenced by state net operating loss write-offs as a result of a change in ownership under section 382 of the Internal Revenue Code in conjunction with the sale of stock by the Asbestos Trust in the first quarter of 2015.
Armstrong World Industries, Inc. designs, manufactures, and sells flooring products and ceiling systems worldwide. The company’s Building Products segment produces suspended mineral fibers, soft fibers, and metal ceiling systems for use in commercial, institutional, and residential settings, in addition to complementary ceiling products; and sells suspension system products.
Finally, Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH), ended its last trade with -4.17% loss, and closed at $43.69.
KYTHERA Biopharmaceuticals, declared it will release its first quarter 2015 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 7, 2015.
The call will be accessible for replay via telephone starting May 7, 2015, at about 5:30 p.m. ET, running through 11:59 p.m. ET on May 13, 2015.
KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
